NDC 68727-745

VYXEOS

(daunorubicin And Cytarabine) Liposome

VYXEOS is a Intravenous Injection, Powder, Lyophilized, For Suspension in the Human Prescription Drug category. It is labeled and distributed by Jazz Pharmaceuticals, Inc.. The primary component is Cytarabine; Daunorubicin.

Product ID68727-745_28c59550-ef14-423e-8cb2-cf4a38339cab
NDC68727-745
Product TypeHuman Prescription Drug
Proprietary NameVYXEOS
Generic Name(daunorubicin And Cytarabine) Liposome
Dosage FormInjection, Powder, Lyophilized, For Suspension
Route of AdministrationINTRAVENOUS
Marketing Start Date2017-08-03
Marketing CategoryNDA / NDA
Application NumberNDA209401
Labeler NameJazz Pharmaceuticals, Inc.
Substance NameCYTARABINE; DAUNORUBICIN
Active Ingredient Strength100 mg/20mL; mg/20mL
Pharm ClassesNucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC],Anthracycline Topoisomerase Inhibitor [EPC],Anthracyclines [CS],Topoisomerase Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 68727-745-01

20 mL in 1 VIAL (68727-745-01)
Marketing Start Date2017-08-03
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 68727-745-02 [68727074502]

VYXEOS INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION
Marketing CategoryNDA
Application NumberNDA209401
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2017-08-03

NDC 68727-745-01 [68727074501]

VYXEOS INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION
Marketing CategoryNDA
Application NumberNDA209401
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2017-08-03

NDC 68727-745-05 [68727074505]

VYXEOS INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION
Marketing CategoryNDA
Application NumberNDA209401
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2017-08-03

Drug Details

Active Ingredients

IngredientStrength
CYTARABINE100 mg/20mL

OpenFDA Data

SPL SET ID:7ea701ce-e7d3-4349-a9c2-642a501d45c8
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 1942748
  • 1942743
  • Pharmacological Class

    • Nucleic Acid Synthesis Inhibitors [MoA]
    • Nucleoside Metabolic Inhibitor [EPC]
    • Anthracycline Topoisomerase Inhibitor [EPC]
    • Anthracyclines [CS]
    • Topoisomerase Inhibitors [MoA]

    Trademark Results [VYXEOS]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    VYXEOS
    VYXEOS
    88265407 not registered Live/Pending
    Celator Pharmaceuticals, Inc.
    2019-01-17
    VYXEOS
    VYXEOS
    86460047 5350908 Live/Registered
    Celator Pharmaceuticals, Inc.
    2014-11-20

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.